Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L. Simpson, Marius Ardeleanu, Thomas Bieber et al.|New England Journal of Medicine|2016Cited by 2k
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis PathogenesisAndrew Blauvelt, Andrea Chiricozzi|Clinical Reviews in Allergy & Immunology|2018Cited by 738
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al.|British Journal of Dermatology|2020Cited by 590
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Marius Ardeleanu, Eric L. Simpson et al.|The Lancet|2015Cited by 566
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman‐Yassky, Alan D. Irvine, Allan R. Tenorio et al.|The Lancet|2021Cited by 538